As of November 4, 2026, Regeneron Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 30, 2026 (Form 8-K, September 30, 2026).
Sell to companies like Regeneron Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Regeneron Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-30. Every row below is cited to the filing it comes from, and this page adds each new change as Regeneron Pharmaceuticals, Inc. files it.
Also on the record for Regeneron Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.37% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 3.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Regeneron Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Regeneron Pharmaceuticals, Inc. and the records around it.
Companies that share a holder
- FMR LLC also filed stake reports on 713 other companies: BRP INC (Oct 2026), CELLDEX THERAPEUTICS INC (Oct 2026), EIKON THERAPEUTICS INC (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2383 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Regeneron Pharmaceuticals, Inc.
Get an email when Regeneron Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Regeneron Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Regeneron Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Regeneron Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-30 | Reported | not named in the filing | 8-K, 2026-09-30 |
New leaders reset buying decisions — get the Full Report on Regeneron Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Regeneron Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Regeneron Pharmaceuticals, Inc.Every change, in the filing's words
Reported
In limited circumstances when the executive's service terminates earlier, the relative TSR adjustment will be measured as of the date of termination.
- The 2026 PSUs reward successful, timely execution by Regeneron's co-founders Drs.
- Schleifer and Yancopoulos against ambitious pipeline and commercial growth goals sustained through the full 10-year performance period, which is aligned with Regeneron's mission, focus on long-term value creation, and product development and commercialization cycles.
- The award structure is a result of a multi-year process led by the Compensation Committee and directly reflects feedback from many of the Company's largest investors, gathered through a dedicated 2026 engagement campaign led by the independent Compensation Committee Chair and Lead Independent Director of the Board.
- Single, 100% performance-based award for ten years; mandatory holding period applies into 2036.
- These one-time awards replace annual equity awards under the Company's long-term incentive plan for the CEO and the CSO until 2036.
- All PSU shares are subject to a mandatory holding period and cannot be sold until February 2036 (the certification date for 2035 performance), with exceptions only for death, disability, or a change in control.
- Rigorous performance goals that reflect Regeneron's strategic objectives.
Tools for this story
Each opens in a new tab, filled in for Regeneron Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.